Dutton Associates Announces Investment Opinion: Arbios Systems Strong Speculative Buy Rating Maintained By Dutton Associates.EL DORADO HILLS, Calif. -- Dutton Associates updates its coverage of Arbios Systems (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ABOS ABOS American Board of Orthopaedic Surgery ) maintaining a Strong Speculative Buy rating and a 12 month $10.80 price target. The 8-page report by Dutton senior analyst Bal Bagwat MD, CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. (R) is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. Arbios received in April 2005 FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval for a clinical trial to test SEPET SEPET System Electrical Performance and Evaluation Test (TM)'s safety and tolerability in patients with acute exacerbation of chronic liver failure liver failure Clinical medicine Liver insufficiency that results in death, requires a liver transplant, or is characterized by recovery after encephalopathy, or while awaiting a transplant; also defined as a condition with ≥ 3 of following: albumin < 3. , which is the largest subset of patients admitted to the hospital in acute liver failure Acute liver failure is the appearance of severe complications rapidly after the first signs of liver disease (such as jaundice), and indicates that the liver has sustained severe damage (loss of function of 80-90% of liver cells). . Arbios is conducting an ongoing SEPET trial for safety and tolerability in a 15-patient, open-label, uncontrolled study being performed at Cedars Sinai Medical Center (Los Angeles) and Albert Einstein Medical Center (Philadelphia). The trial was initiated in July 2005 and is anticipated to conclude in early 2006. A larger, controlled study in approximately 10 medical centers will be proposed in 2006, following FDA approval. SEPET is a disposable selective plasma filtration cartridge used with a standard renal dialysis machine that does not require additional capital outlay capital outlay See capital expenditure. by medical centers. Preliminary clinical studies show SEPET is also unique in its ability to remove inhibitors of hepatic growth and mediators of inflammation from the patient's serum. Arbios management will meet with the FDA later in 2005 to discuss instituting a new phase 3 trial to evaluate HepatAssist-2(TM), a bioartificial liver cartridge containing more porcine porcine /por·cine/ (por´sin) pertaining to swine. porcine pertaining to pig. See also hog (1), swine. porcine circovirus 1 a nonpathogenic virus. hepatocytes and a new multifunctional platform. The potential U.S. market for selective plasma filtration products is estimated to be $900 million, and could be significantly higher if additional medical conditions such as septic shock are found to benefit from selective plasma filtration or bioartificial liver dialysis therapy. About Dutton Associates Dutton Associates is one of the largest independent investment research firms in the U.S. Its 27 senior analysts are primarily CFAs, and have expertise in many industries. Dutton & Associates provides continuing analyst coverage of over 120 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors. The cost of enrollment in our one-year continuing research program is US $33,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton & Associates received $33,000 from the Company for 4 Research Reports with coverage commencing on 1/24/2005. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion